RTP Mobile Logo
Breast Cancer Update, Issue 3, 2019 (Video Program)
Released October 2019

Featuring interviews with Drs Matthew Goetz and Virginia Kaklamani on the management of hormone receptor-positive breast cancer. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, hematologist-oncologists and other healthcare providers involved in the treatment of breast cancer.

    Breast cancer remains the most frequently diagnosed cancer in women, and in 2019 in the United States alone the disease will culminate in an estimated 271,270 new cases and 42,260 deaths. Estrogen receptor (ER)-positive disease, which represents approximately 65% of all cases, is perhaps the most nuanced subset in regard to therapeutic decision-making in the advanced setting. In recent years several ground-breaking clinical data sets and related FDA actions have significantly and unprecedentedly altered the treatment algorithm for patients with ER-positive breast cancer. With these exciting advances, many areas of controversy, vexing questions and clinical challenges are emerging. To provide clinicians with therapeutic strategies to address the disparate needs of patients with ER-positive breast cancer, this program will feature one-on-one discussions with leading breast cancer investigators. By providing information on the latest clinical developments in the context of expert perspectives, this activity will assist medical oncologists with the formulation of evidence-based and current therapeutic strategies, which will in turn facilitate optimal patient care.


    • Implement a clinical plan for the management of ER-positive metastatic breast cancer, considering available data and patient and disease characteristics.
    • Appraise published efficacy and safety data with the FDA-approved CDK4/6 inhibitors abemaciclib, palbociclib and ribociclib, and determine how they can be optimally integrated into the management of ER-positive advanced breast cancer.
    • Consider the recent FDA approval of and available Phase III data with alpelisib in combination with fulvestrant for patients with ER-positive advanced breast cancer with a PIK3CA mutation, and determine how this regimen can be incorporated into clinical practice.
    • Recognize the evolving application of biomarkers and multigene assays in breast cancer management, and effectively use these tools to refine or individualize treatment plans for patients with localized disease.
    • Appreciate the role of adjuvant endocrine therapy versus chemoendocrine therapy for women with ER-positive, HER2-negative, node-negative breast cancer and an intermediate 21-gene Recurrence Score®.
    • Develop an understanding of the mechanisms of action of, available data with and potential clinical roles of novel agents and approaches in the management of ER-positive breast cancer to facilitate referral for clinical trial opportunities.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Matthew Goetz, MD
    Professor of Oncology and Pharmacology
    Mayo Clinic
    Rochester, Minnesota

    Advisory Committee: bioTheranostics Inc, Biovica, Context Therapeutics, Lilly, Novartis, Pfizer Inc, Sermonix Pharmaceuticals.

    Virginia Kaklamani, MD, DSc
    Professor of Medicine
    Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
    AB Alexander Distinguished Chair in Oncology
    Associate Director for Clinical Research
    Leader of the Breast Cancer Program
    UT Health San Antonio
    The University of Texas MD Anderson Cancer Center
    San Antonio, Texas

    Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Athenex, Celldex Therapeutics, Eisai Inc, Puma Biotechnology Inc; Contracted Research: Eisai Inc; Speakers Bureau: Celgene Corporation, Eisai Inc, Genentech, Genomic Health Inc, Novartis, Pfizer Inc, Puma Biotechnology Inc.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Celgene Corporation, Daiichi Sankyo Inc, Genentech, Genomic Health Inc, Lilly, Merck, Novartis, Puma Biotechnology Inc and Seattle Genetics.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: October 2019
    Expiration date: October 2020

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):

Interview with Matthew Goetz, MD

Interview with Virginia Kaklamani, MD, DSc

Select Publications